Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
Journal of Translational Medicine|July 16, 2010
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Jill C Rubinstein, Mario Sznol, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2011
Plasma markers for identifying patients with metastatic melanomaHarriet M Kluger, Kathleen Hoyt, Antonella Bacchiocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Ivan King, et al.
Pigment Cell & Melanoma Research|February 13, 2010
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cellsRuth Halaban, Wengeng Zhang, Antonella Bacchiocchi, et al.
JAAD International|May 30, 2023
Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerabilityAnnika Belzer, Jolanta Pach, Ryland D Mortlock, et al.
Pigment Cell & Melanoma Research|July 29, 2024
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy eraDaniel Y Lee, Madeline McNamara, Alexander Yang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
A clinical development paradigm for cancer vaccines and related biologicsAxel Hoos, Giorgio Parmiani, Kristen Hege, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2020
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I StudyDmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, et al.
Genome Research|June 4, 2009
Genome-wide screen of promoter methylation identifies novel markers in melanomaYasuo Koga, Mattia Pelizzola, Elaine Cheng, et al.
Immunological Reviews|July 26, 2023
CD4 T cells and toxicity from immune checkpoint blockadeNoah Earland, Wubing Zhang, Abul Usmani, et al.
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
Journal of Translational Medicine|July 16, 2010
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Jill C Rubinstein, Mario Sznol, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2011
Plasma markers for identifying patients with metastatic melanomaHarriet M Kluger, Kathleen Hoyt, Antonella Bacchiocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Ivan King, et al.
Pigment Cell & Melanoma Research|February 13, 2010
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cellsRuth Halaban, Wengeng Zhang, Antonella Bacchiocchi, et al.
JAAD International|May 30, 2023
Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerabilityAnnika Belzer, Jolanta Pach, Ryland D Mortlock, et al.
Pigment Cell & Melanoma Research|July 29, 2024
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy eraDaniel Y Lee, Madeline McNamara, Alexander Yang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
A clinical development paradigm for cancer vaccines and related biologicsAxel Hoos, Giorgio Parmiani, Kristen Hege, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2020
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I StudyDmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, et al.
Genome Research|June 4, 2009
Genome-wide screen of promoter methylation identifies novel markers in melanomaYasuo Koga, Mattia Pelizzola, Elaine Cheng, et al.
Immunological Reviews|July 26, 2023
CD4 T cells and toxicity from immune checkpoint blockadeNoah Earland, Wubing Zhang, Abul Usmani, et al.
Pageof 19